The move is expected to delay the introduction of low-priced medicines in the market.
Official sources said Sun Pharma and two major industry bodies -- the Indian Drug Manufacturers Association and the Confederation of Indian Pharmaceutical Industry -- had recently approached the Delhi High Court, challenging the 45-day period given to companies to replace existing stocks.
Besides, firms such as IPCA Labs and multinational drug maker Abbott had filed a review petition with the Department of Pharmaceuticals, challenging other aspects of the new price regulation, sources said.
The National Pharmaceutical Pricing Authority, the pricing regulator, had started notifying the prices of essential medicines, according to the new policy, from mid-June.
The notification said companies were required to replace existing stocks in the market with newly priced batches within 45
9 drug firms may have to gulp Rs 2.5k-cr pill
Markets erase early gains, Midcap index down 1%
Govt to review suspension of 3 drugs
Drug makers pay lip service to R&D in India
Former cricket captain Azharuddin fighting for badminton now!